205 related articles for article (PubMed ID: 37762498)
1. The Potential for Targeting AVIL and Other Actin-Binding Proteins in Rhabdomyosarcoma.
Cornelison R; Marrah L; Fierti A; Piczak C; Glowczyk M; Tajammal A; Lynch S; Li H
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762498
[TBL] [Abstract][Full Text] [Related]
2. Rhabdomyosarcomas are oncogene addicted to the activation of AVIL.
Xie Z; Janczyk PL; Shi X; Wang Q; Singh S; Cornelison R; Xu J; Mandell JW; Barr FG; Li H
Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2118048119. PubMed ID: 37146302
[TBL] [Abstract][Full Text] [Related]
3. A cytoskeleton regulator AVIL drives tumorigenesis in glioblastoma.
Xie Z; Janczyk PŁ; Zhang Y; Liu A; Shi X; Singh S; Facemire L; Kubow K; Li Z; Jia Y; Schafer D; Mandell JW; Abounader R; Li H
Nat Commun; 2020 Jul; 11(1):3457. PubMed ID: 32651364
[TBL] [Abstract][Full Text] [Related]
4. Advillin acts upstream of phospholipase C ϵ1 in steroid-resistant nephrotic syndrome.
Rao J; Ashraf S; Tan W; van der Ven AT; Gee HY; Braun DA; Fehér K; George SP; Esmaeilniakooshkghazi A; Choi WI; Jobst-Schwan T; Schneider R; Schmidt JM; Widmeier E; Warejko JK; Hermle T; Schapiro D; Lovric S; Shril S; Daga A; Nayir A; Shenoy M; Tse Y; Bald M; Helmchen U; Mir S; Berdeli A; Kari JA; El Desoky S; Soliman NA; Bagga A; Mane S; Jairajpuri MA; Lifton RP; Khurana S; Martins JC; Hildebrandt F
J Clin Invest; 2017 Dec; 127(12):4257-4269. PubMed ID: 29058690
[TBL] [Abstract][Full Text] [Related]
5. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.
Crose LE; Etheridge KT; Chen C; Belyea B; Talbot LJ; Bentley RC; Linardic CM
Clin Cancer Res; 2012 Jul; 18(14):3780-90. PubMed ID: 22648271
[TBL] [Abstract][Full Text] [Related]
6. Targeting AVIL, a New Cytoskeleton Regulator in Glioblastoma.
Cornelison R; Marrah L; Horter D; Lynch S; Li H
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948433
[TBL] [Abstract][Full Text] [Related]
7. Expression of oncogenic HRAS in human Rh28 and RMS-YM rhabdomyosarcoma cells leads to oncogene-induced senescence.
Li JJ; Kovach AR; DeMonia M; Slemmons KK; Oristian KM; Chen C; Linardic CM
Sci Rep; 2021 Aug; 11(1):16505. PubMed ID: 34389744
[TBL] [Abstract][Full Text] [Related]
8. Oxytocin receptor disruption in Avil-expressing cells results in blunted sociability and increased inter-male aggression.
Tabbaa M; Moses A; Hammock EAD
PLoS One; 2021; 16(11):e0260199. PubMed ID: 34847180
[TBL] [Abstract][Full Text] [Related]
9. Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.
Dasgupta A; Sierra L; Tsang SV; Kurenbekova L; Patel T; Rajapakse K; Shuck RL; Rainusso N; Landesman Y; Unger T; Coarfa C; Yustein JT
Cancer Res; 2021 Jan; 81(1):199-212. PubMed ID: 33168646
[TBL] [Abstract][Full Text] [Related]
10. Sclerosing rhabdomyosarcoma in adults: report of four cases of a hyalinizing, matrix-rich variant of rhabdomyosarcoma that may be confused with osteosarcoma, chondrosarcoma, or angiosarcoma.
Folpe AL; McKenney JK; Bridge JA; Weiss SW
Am J Surg Pathol; 2002 Sep; 26(9):1175-83. PubMed ID: 12218574
[TBL] [Abstract][Full Text] [Related]
11. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
Laé M; Ahn EH; Mercado GE; Chuai S; Edgar M; Pawel BR; Olshen A; Barr FG; Ladanyi M
J Pathol; 2007 Jun; 212(2):143-51. PubMed ID: 17471488
[TBL] [Abstract][Full Text] [Related]
12. FOXM1 expression in rhabdomyosarcoma: a novel prognostic factor and therapeutic target.
Kuda M; Kohashi K; Yamada Y; Maekawa A; Kinoshita Y; Nakatsura T; Iwamoto Y; Taguchi T; Oda Y
Tumour Biol; 2016 Apr; 37(4):5213-23. PubMed ID: 26553361
[TBL] [Abstract][Full Text] [Related]
13. Tumor suppressive functions of WNT5A in rhabdomyosarcoma.
Ragab N; Bauer J; Uhmann A; Marx A; Hahn H; Simon-Keller K
Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35796028
[TBL] [Abstract][Full Text] [Related]
14. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.
van Gaal JC; Roeffen MH; Flucke UE; van der Laak JA; van der Heijden G; de Bont ES; Suurmeijer AJ; Versleijen-Jonkers YM; van der Graaf WT
Eur J Cancer; 2013 Nov; 49(16):3462-70. PubMed ID: 23867124
[TBL] [Abstract][Full Text] [Related]
16. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma.
Zibat A; Missiaglia E; Rosenberger A; Pritchard-Jones K; Shipley J; Hahn H; Fulda S
Oncogene; 2010 Dec; 29(48):6323-30. PubMed ID: 20818440
[TBL] [Abstract][Full Text] [Related]
17. NELL1, whose high expression correlates with negative outcomes, has different methylation patterns in alveolar and embryonal rhabdomyosarcoma.
Tombolan L; Poli E; Martini P; Zin A; Romualdi C; Bisogno G; Lanfranchi G
Oncotarget; 2017 May; 8(20):33086-33099. PubMed ID: 28380437
[TBL] [Abstract][Full Text] [Related]
18. The discovery of AVIL as a
Xie Z; Li H
Mol Cell Oncol; 2020; 7(6):1804309. PubMed ID: 33241106
[TBL] [Abstract][Full Text] [Related]
19. Variation in cadherins and catenins expression is linked to both proliferation and transformation of Rhabdomyosarcoma.
Charrasse S; Comunale F; Gilbert E; Delattre O; Gauthier-Rouvière C
Oncogene; 2004 Mar; 23(13):2420-30. PubMed ID: 14691446
[TBL] [Abstract][Full Text] [Related]
20. PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound.
Cen L; Hsieh FC; Lin HJ; Chen CS; Qualman SJ; Lin J
Br J Cancer; 2007 Sep; 97(6):785-91. PubMed ID: 17848913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
